- Ongoing Phase 2 study enrolling 102 patients in the U.S. and South Korea, with more than 50% of participants identified as Asian - Selectively inhibits collagen synthesis via PRS targeting, aiming to suppressing fibrosis progression SEOUL, June 4, 2025 /PRNewswire/ -- Daewoong...
Read More Details
Finally We wish PressBee provided you with enough information of ( Daewoong Pharmaceutical Presents Phase 2 Clinical Trial Poster on 'Bersiporocin' at ATS 2025, Highlights Global Patient Demographics )
Also on site :
- Adorable Elephant Breaks Free From National Park and Heads Right to the Snack Aisle at the Grocery Store
- Chicago Forecast: Pleasant temperatures, mostly cloudy skies ahead of possible evening rain
- Yemen’s al-Qaida branch leader threatens Trump, Musk and others